Literature DB >> 19453346

Considerations before choosing (extemporaneously) compounded products.

Lincoln Krochmal1.   

Abstract

Despite a plethora of pre-packaged topical products produced by the pharmaceutical industry for treating skin diseases, the practice of extemporaneous compounding continues, albeit at a low level (<1% of prescriptions). Sourcing prescription compounding services via the Internet has increased dramatically in recent years, posing new risks to patients and prescribing physicians. The technical, economic, and medico-legal issues associated with the practice of ad hoc compounding are reviewed and updated. A practical set of recommendations are provided for prescribing physicians and their recipient patients with the hope that, if followed, they will reduce the potential risks associated with the use of products that are formulated extemporaneously.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453346     DOI: 10.1111/j.1529-8019.2009.01235.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing.

Authors:  Claudio Giuliano; Stefano Frizzarin; Alessandro Alonzi; Virginia Stimamiglio; Pablo L Ortiz-Romero
Journal:  Dermatol Ther (Heidelb)       Date:  2022-10-14

2.  Pharmacy compounding primer for physicians: prescriber beware.

Authors:  Sarah Sellers; Wulf H Utian
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.